Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 154

1.

Patient characteristics and the likelihood of initiation on olanzapine or risperidone among patients with schizophrenia.

Ren XS, Kazis LE, Lee AF, Huang YH, Hamed A, Cunningham F, Herz L, Miller DR.

Schizophr Res. 2005 Sep 15;77(2-3):167-77.

PMID:
15894460
2.

Initiation of atypical antipsychotic agents and health outcomes in patients with schizophrenia.

Ren XS, Lee AF, Huang YH, Hamed A, Herz L, Miller DR, Kazis LE.

J Clin Pharm Ther. 2004 Oct;29(5):471-81.

PMID:
15482392
3.

Treatment persistence: a comparison among patients with schizophrenia who were initiated on atypical antipsychotic agents.

Ren XS, Qian S, Lee AF, Herz L, Miller DR, Kazis LE.

J Clin Pharm Ther. 2006 Feb;31(1):57-65.

PMID:
16476121
4.

Association of co-morbidities with prescribing patterns and cost savings: olanzapine versus risperidone for schizophrenia.

Yu W, Ren XS, Lee AF, Herz L, Huang YH, Kazis LE.

Pharmacoeconomics. 2006;24(12):1233-48.

PMID:
17129077
5.

Ethnicity and prescription patterns for haloperidol, risperidone, and olanzapine.

Opolka JL, Rascati KL, Brown CM, Gibson PJ.

Psychiatr Serv. 2004 Feb;55(2):151-6.

PMID:
14762239
6.

Patient characteristics and prescription patterns of atypical antipsychotics among patients with schizophrenia.

Ren XS, Kazis LE, Lee AF, Hamed A, Huang YH, Cunningham F, Miller DR.

J Clin Pharm Ther. 2002 Dec;27(6):441-51.

PMID:
12472984
7.

Adjunctive use of atypical antipsychotics and anticholinergic drugs among patients with schizophrenia.

Ren XS, Huang YH, Lee AF, Miller DR, Qian S, Kazis L.

J Clin Pharm Ther. 2005 Feb;30(1):65-71.

PMID:
15659005
8.

[Antipsychotics in bipolar disorders].

Vacheron-Trystram MN, Braitman A, Cheref S, Auffray L.

Encephale. 2004 Sep-Oct;30(5):417-24. Review. French.

PMID:
15627046
10.

[Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].

Llorca PM, Miadi-Fargier H, Lançon C, Jasso Mosqueda G, Casadebaig F, Philippe A, Guillon P, Mehnert A, Omnès LF, Chicoye A, Durand-Zaleski I.

Encephale. 2005 Mar-Apr;31(2):235-46. Review. French.

PMID:
15959450
11.
12.

Cost of antipsychotic polypharmacy in the treatment of schizophrenia.

Zhu B, Ascher-Svanum H, Faries DE, Correll CU, Kane JM.

BMC Psychiatry. 2008 Apr 4;8:19. doi: 10.1186/1471-244X-8-19.

14.

Determinants of atypical antipsychotic use among antipsychotic users in community-dwelling elderly, 1996-2004.

Jano E, Johnson M, Chen H, Aparasu RR.

Curr Med Res Opin. 2008 Mar;24(3):709-16. doi: 10.1185/030079908X260989. Epub 2008 Jan 25.

PMID:
18226325
15.

Health care costs for schizophrenia patients started on olanzapine versus risperidone.

Russo PA, Smith MW, Namjoshi M.

Am J Health Syst Pharm. 2005 Mar 15;62(6):610-5.

PMID:
15757882
16.
17.

Factors associated with the prescribing of olanzapine, quetiapine, and risperidone in patients with bipolar and related affective disorders.

Prabhakar M, Haynes WG, Coryell WH, Chrischilles EA, Miller del D, Arndt S, Ellingrod VL, Warren L, Fiedorowicz JG.

Pharmacotherapy. 2011 Aug;31(8):806-12. doi: 10.1592/phco.31.8.806.

18.

Diagnoses associated with use of atypical antipsychotics in a commercial health plan: a claims database analysis.

Citrome L, Kalsekar I, Guo Z, Laubmeier K, Hebden T.

Clin Ther. 2013 Dec;35(12):1867-75. doi: 10.1016/j.clinthera.2013.09.006. Epub 2013 Oct 8.

19.

Pharmacy cost evaluation of risperidone, olanzapine, and quetiapine for the treatment of schizophrenia in acute care inpatient settings.

Mladsi DM, Grogg AL, Irish WD, Lopez RB, Degen K, Swann A, Nimsch CT.

Curr Med Res Opin. 2004 Dec;20(12):1883-93.

PMID:
15701206
20.

Supplemental Content

Support Center